MedTrace Logo

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

NCT03878706 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2026-03-13

No results posted yet for this study

Summary

A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment:

* 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin
* 60 patients treated with GLP-1 agonist as a second step after metformin
* 60 patients treated with SGLT2 inhibitor as a second step after metformin
* 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Ignatios Ikonomidis, Prof · 2nd Department of Cardiology, National and Kapodistrian University of Athens

  • Aimilianos N. Kalogeris, MD · 2nd Department of Cardiology, University of Athens

  • John A. Thymis, MD · 2nd Department of Cardiology,University of Athens

  • Vaia Lambadiari, Prof. · National and Kapodistrian University of Athens

  • Georgios Dimitriadis, Prof. · National and Kapodistrian University of Athens

  • Efstathios Iliodromitis, Prof. · National and Kapodistrian University of Athens

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-03
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03878706 on ClinicalTrials.gov